Ahead of this year's Extractables & Leachables Asia, we spoke with Paavo Sillanpää, Global Senior Manager Business Development, Pharma at UPM Raflatac,​ learn more about what he shared with us below!






Q1  We are really looking forward to hearing your presentation. Can you give us a bit of taste of what you will be sharing at the conference?

I will be discussing the critical importance of label materials in E&L studies and the potential risks of using standard materials in pharmaceutical applications. I will also share insight into how a label stock manufacturer can help end users in their E&L studies.   Focusing on packaging and label material selection early enough in the drug development process helps to mitigate potential delays and problems in later stages of the approval process.

Q2  What do you think is the most challenging part at this point for pharma packaging?

The challenges in pharmaceutical labeling are multifaceted, involving the need to accommodate small diameter containers, ensure adhesives have low leachable characteristics, are biocompatible,  withstand various sterilization methods and cold temperature performance to mention a few.  Addressing these challenges requires an in-depth understanding of material science and regulatory requirements, something we are well-versed in and continue to evolve with industry needs.

Q3  What are you most looking forward to at E&L Asia 2024?

I am definitely looking forward to dialogue with the participants concerning the local  (APAC)  regulatory requirements relevant for pharmaceutical labels and how they will be aligned with the requirements of EMA and FDA. Asian pharmaceutical exporting to Europe and USA obviously need to comply with the local legislation and guidance and  these conversations are crucial for advancing our collective understanding and ensuring our pharma-dedicated labeling solutions meet  required performance and safety standards.